NASDAQ:XGN - Exagen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.00
  • Forecasted Upside: 80.06 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$14.44
▲ +0.62 (4.49%)

This chart shows the closing price for XGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XGN

Analyst Price Target is $26.00
▲ +80.06% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Exagen in the last 3 months. The average price target is $26.00, with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 80.06% upside from the last price of $14.44.

This chart shows the closing price for XGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Exagen.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/10/2021BTIG ResearchLower Price TargetBuy$23.00 ➝ $20.00High
7/9/2021Cantor FitzgeraldReiterated RatingOverweightLow
4/15/2021Canaccord GenuityInitiated CoverageBuy$25.00Medium
3/17/2021CowenBoost Price TargetOutperform$21.00 ➝ $26.00Medium
3/2/2021KeyCorpBoost Price TargetOverweight$32.00 ➝ $33.00High
11/11/2020William BlairReiterated RatingOutperformMedium
11/10/2020KeyCorpInitiated CoverageOverweight$32.00Low
11/9/2020KeyCorpInitiated CoverageOverweightLow
10/8/2020BTIG ResearchInitiated CoverageBuy$18.00High
6/1/2020Cantor FitzgeraldInitiated CoverageOverweight$19.00 ➝ $20.00Low
5/21/2020Cantor FitzgeraldReiterated RatingOverweightHigh
3/26/2020Cantor FitzgeraldLower Price TargetOverweight$25.00 ➝ $19.00High
3/2/2020Cantor FitzgeraldReiterated RatingBuy$25.00High
10/14/2019Cantor FitzgeraldInitiated CoverageOverweight$18.00Low
10/14/2019William BlairInitiated CoverageOutperformLow
10/14/2019CowenInitiated CoverageOutperform$17.00Low
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/21/2021
  • 4 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/20/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Exagen logo
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Read More

Today's Range

Now: $14.44
Low: $13.06
High: $14.53

50 Day Range

MA: $13.03
Low: $10.25
High: $14.44

52 Week Range

Now: $14.44
Low: $10.13
High: $24.67

Volume

111,904 shs

Average Volume

69,982 shs

Market Capitalization

$232.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Exagen?

The following sell-side analysts have issued research reports on Exagen in the last year: BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Cowen Inc, KeyCorp, TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for XGN.

What is the current price target for Exagen?

4 Wall Street analysts have set twelve-month price targets for Exagen in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 80.1%. KeyCorp has the highest price target set, predicting XGN will reach $33.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $20.00 for Exagen in the next year.
View the latest price targets for XGN.

What is the current consensus analyst rating for Exagen?

Exagen currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XGN will outperform the market and that investors should add to their positions of Exagen.
View the latest ratings for XGN.

What other companies compete with Exagen?

How do I contact Exagen's investor relations team?

Exagen's physical mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The company's listed phone number is 760-560-1501 and its investor relations email address is [email protected] The official website for Exagen is www.exagen.com.